<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">WILSON, ASHLEY</style></author><author><style face="normal" font="default" size="100%">SMALL, JAMES</style></author><author><style face="normal" font="default" size="100%">FLANAGAN, CATHERINE</style></author><author><style face="normal" font="default" size="100%">PERRY, DAVID</style></author><author><style face="normal" font="default" size="100%">MARCHELL, RICHARD</style></author><author><style face="normal" font="default" size="100%">THIERS, BRUCE</style></author><author><style face="normal" font="default" size="100%">ALBERG, ANTHONY J.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Keratinocyte Carcinoma and Risk for Another Type of Cancer: Assessment of a Dose-response Relationship</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5083-5087</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.13702</style></doi><volume><style face="normal" font="default" size="100%">39</style></volume><issue><style face="normal" font="default" size="100%">9</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Keratinocyte carcinoma (KC) is a marker of increased risk of other cancer types. To assess if this association exhibits a dose-response relationship, a case-control study was carried out. Patients and Methods: This was a clinic-based study of cases with KC plus another type of cancer matched by age, race (all Caucasian), sex and histologic type to controls with KC only (n=48 matched pairs). Results: Compared with the KC only group, those with KC plus another cancer had a mean number of lesions that were 43%, 35%, and 41% greater for basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and total KC, respectively. The odds ratio (OR) of developing another type of cancer increased from 1.0 to 1.09 (95% confidence interval (CI)=0.23-5.13) to 2.12 (95%CI=0.50-9.08) according to whether the patient had zero, one, or ≥two BCC lesions; for SCC, the corresponding ORs were 1.0, 1.24 (95%CI=0.48-3.24), and 1.39 (95%CI=0.29-6.61). Conclusion: A dose-response relationship seems to exist between the number of skin lesions and the risk of another type of cancer, but the lack of statistical significance weakens this evidence.</style></abstract></record></records></xml>